Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee hears bill to exempt FDA‑approved crystalline polymorph psilocybin from Kansas Schedule I
Summary
Witnesses and committee members discussed House Bill 2218, which would amend Kansas law to exclude FDA‑approved pharmaceutical crystalline polymorph psilocybin from the Schedule I controlled substances list and add such FDA‑approved products to Schedule IV once federal approvals and state certification occur.
The Committee on House Health and Human Services held a hearing on House Bill 2218, a bill that would amend the Kansas Uniform Controlled Substances Act to exclude an FDA‑approved pharmaceutical composition of crystalline polymorph psilocybin from the Schedule I definition and to add any such FDA‑approved product to Schedule IV after federal approvals and state certification.
Carly, committee staff, summarized the bill’s sections and the procedural trigger: the bill would take effect after an FDA approval of a pharmaceutical crystalline polymorph psilocybin product, followed by certification by the attorney general and publication by the secretary of state. Carly told the committee the text amends KSA 65-41-01 (definitions) and KSA 65-41-11…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
